Celgene Co. (NASDAQ:CELG) Shares Sold by Stock Yards Bank & Trust Co.

Stock Yards Bank & Trust Co. decreased its position in shares of Celgene Co. (NASDAQ:CELG) by 89.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,912 shares of the biopharmaceutical company’s stock after selling 124,948 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Celgene were worth $1,407,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CELG. Oregon Public Employees Retirement Fund raised its holdings in Celgene by 9,691.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 16,495,997 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 16,327,522 shares during the last quarter. Norges Bank acquired a new stake in Celgene during the 4th quarter valued at approximately $484,390,000. Parnassus Investments CA increased its position in Celgene by 1,766.7% during the 4th quarter. Parnassus Investments CA now owns 2,800,000 shares of the biopharmaceutical company’s stock valued at $179,452,000 after purchasing an additional 2,650,000 shares during the period. BlackRock Inc. increased its position in Celgene by 2.8% during the 4th quarter. BlackRock Inc. now owns 53,650,909 shares of the biopharmaceutical company’s stock valued at $3,438,486,000 after purchasing an additional 1,459,100 shares during the period. Finally, Candriam Luxembourg S.C.A. increased its position in Celgene by 64.2% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 2,111,324 shares of the biopharmaceutical company’s stock valued at $135,309,000 after purchasing an additional 825,120 shares during the period. 72.01% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ CELG traded up $0.04 during midday trading on Friday, hitting $95.51. 4,976,019 shares of the company’s stock were exchanged, compared to its average volume of 5,989,271. The firm has a market capitalization of $67.36 billion, a price-to-earnings ratio of 12.55, a PEG ratio of 0.44 and a beta of 1.68. Celgene Co. has a 12-month low of $58.59 and a 12-month high of $97.07. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 2.42.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.45 by $0.10. Celgene had a return on equity of 106.69% and a net margin of 30.10%. The company had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.01 billion. During the same quarter in the previous year, the company posted $2.05 EPS. Celgene’s quarterly revenue was up 13.8% compared to the same quarter last year. On average, analysts predict that Celgene Co. will post 9.85 earnings per share for the current year.

CELG has been the subject of several recent analyst reports. Cantor Fitzgerald downgraded shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 price objective for the company. in a research report on Friday, April 5th. ValuEngine downgraded shares of Celgene from a “hold” rating to a “sell” rating in a research report on Wednesday, April 24th. BidaskClub downgraded shares of Celgene from a “hold” rating to a “sell” rating in a research report on Thursday, April 25th. Cowen began coverage on shares of Celgene in a research report on Tuesday, February 26th. They issued a “market perform” rating and a $102.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Celgene from a “buy” rating to a “hold” rating in a research report on Wednesday, April 3rd. Twenty research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $95.96.

In related news, Director Ernest Mario acquired 2,000 shares of the stock in a transaction on Tuesday, February 12th. The stock was purchased at an average price of $89.99 per share, for a total transaction of $179,980.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/12/stock-yards-bank-trust-co-trims-position-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Article: How to Track your Portfolio in Google Finance

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.